Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer
Terminated · Phase 1 · NCT04982224
Conditions: Advanced NSCLC
At a glance
- Research payments reported, 2025
- $380,885
- U.S. investigators named
- 12
- Sites paid
- 10
- Planned or actual enrollment
- 30
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- REGN5093-M114 (drug), Cemiplimab (drug)
- Dates
- Started 2021-11-09; completion 2025-10-15
- Results posted
- Not yet
This study is researching an experimental drug called REGN5093-M114 by itself and in combination with cemiplimab. The study is focused on advanced non-small cell lung cancer (NSCLC) that produces too much of a protein called mesenchymal epithelial transition factor (MET) on the cancer cell surface. The aim of the study is to see how safe, tolerable, and effective the study drug is. This study will include 3 study groups, or cohorts, and each group is split into 2 parts: Part 1: The main purpose of part 1 is to determine a safe dose of REGN5093-M114 (Cohorts A and B), and in combination with cemiplimab (Cohort C). Part 2: The main purpose of part 2 is to use the REGN5093-M114 dose found fo…
From ClinicalTrials.gov, last updated 2025-11-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $380,885 in research payments for this study in 2025 (55 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Sai-hong I Ou, MD Hematology & Oncology · Orange, CA
- David Camidge, MD Medical Oncology · Aurora, CO
- Julia K. Rotow, MD Medical Oncology · Boston, MA
- Patrick Forde, M.D. Hematology & Oncology · Baltimore, MD
- Kristen Marrone, M.D. Internal Medicine · Baltimore, MD
- Shirish M. Gadgeel, MD Medical Oncology · Detroit, MI
- Mark M. Awad, MD, PHD Medical Oncology · New York, NY
- Alexander Edward D. Drilon, MD Medical Oncology · New York, NY
- Liza C. Villaruz, M.D. Internal Medicine · Pittsburgh, PA
- Mariam Alexander Medical Oncology · Charleston, SC
- George R. Blumenschein JR., M.D. Medical Oncology · Houston, TX
- Alexander I. Spira, M.D. Medical Oncology · Fairfax, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Memorial Sloan Kettering Cancer Center $143,284
- Ut MD Anderson Cancer Center $85,922
- Dana Farber Mass General Brigham Cancer Care Inc $79,824
- Uci Health-Orange, CA $20,428
- Henry Ford Health Hospital, MI $18,292
- University of Pittsburgh Cancer Institute Cancer Services $11,498
- Johns Hopkins University $10,871
- Virginia Cancer Specialists PC $7,675
- Regents of the University of Colorado $2,508
- Medical University of South Carolina $584
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.